Australie - anglais - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; glycerol; iron oxide yellow; polysorbate 80; iron oxide red - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 100 mg; benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg) - tablet, uncoated - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; docusate sodium; iron oxide red; calcium hydrogen phosphate; magnesium stearate; ethylcellulose; mannitol - parkinson's disease and parkinsonian symptoms including post- encephalitic and toxic forms, but excluding drug induced parkinsonism.

États-Unis - anglais - NLM (National Library of Medicine)

wockhardt usa llc. - levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t), carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh) - levodopa 50 mg - carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-o-methyltransferase-comt inhibitor) is indicated for the treatment of parkinson's disease. carbidopa, levodopa and entacapone tablets can be used: - to substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products. - to replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose "wearing-off" and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias. carbidopa, levodopa and entacapone tablets are contraindicated in patients: - taking nonselective monoamine oxidase (mao) inhibitors (e.g., phenelzine and tranylcypromine). these nonselective mao inhibitors must be discontinued at least two weeks prior to in

Australie - anglais - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; microcrystalline cellulose; carmellose sodium; hyprolose; sodium sulfate; magnesium stearate; powdered cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Union européenne - anglais - EMA (European Medicines Agency)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - anti-parkinson drugs - corbilta is indicated for the treatment of adult patients with parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Irlande - anglais - HPRA (Health Products Regulatory Authority)

roche products (ireland) ltd - levodopa; benserazide - dispersible tablet - 50 mg/12.5 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Irlande - anglais - HPRA (Health Products Regulatory Authority)

roche products (ireland) ltd - levodopa; benserazide - dispersible tablet - 100 mg/25 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Irlande - anglais - HPRA (Health Products Regulatory Authority)

roche products (ireland) ltd - levodopa; benserazide - capsule, hard - 200 mg/50 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Australie - anglais - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; hyprolose; magnesium stearate; microcrystalline cellulose; sodium sulfate; carmellose sodium; powdered cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.